Recombinant Human Uteroglobin Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-4755

Recombinant Human Uteroglobin Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-4755
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession P11684
Synonym CC10, CC16, CCPBP, CCSP, UGB, UP-1, UP1
Background Uteroglobin (UG), also known as Secretoglobin 1A member 1 (SCGB1A1), Blastokinin, Clara cell secretor protein (CCSP) or Clara cell-specific 1-kDa protein (CC1), is the founding member of the secretoglobin family of small, secreted, disulfide-bridged dimeric proteins found only in mammals. This protein is mainly expressed in lung, with anti-inflammatory/immunomodulatory properties. Previous in vitro studies demonstrated that CCAAT/enhancer-binding proteins (C/EBPs) are the major transcription factors for the regulation of SCGB1A1 gene expression, whereas FOXA1 had a minimum effect on the transcription. Uteroglobin is a multifunctional protein with antiinflammatory/immunomodulatory properties. Uteroglobin inhibits soluble phospholipase A(2) activity and binds and perhaps sequesters hydrophobic ligands such as progesterone, retinols, polychlorinated biphenyls, phospholipids, and prostaglandins. In addition to its antiinflammatory activities, Uteroglobin manifests antichemotactic, antiallergic, antitumorigenic, and embryonic growth-stimulatory activities. The tissue-specific expression of the Uteroglobin gene is regulated by several steroid hormones, although a nonsteroid hormone, prolactin, further augments its expression in the uterus. Based on its anti-inflammatory and antiallergic properties, Uteroglobin is a potential drug target. The mechanism of Uteroglobin action is likely to be even more complex as it also functions via a putative receptor-mediated pathway.
Description A DNA sequence encoding the human SCGB1A1 (P11684) (Met 1-Asn 91) was expressed, with a C-terminal His tag.
Source HEK293
Predicted N Terminal Glu 22
AA Sequence Met 1-Asn 91
Molecular Weight The recombinant human SCGB1A1 consists of 81 a.a. and migrates as a 9.2 kDa band as predicted in SDS-PAGE under reducing conditions.
Purity >97% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Measured by the ability of the immobilized protein to support the adhesion of the A549 human lung carcinoma cell line. When 5 x 10E4cells/well are added to human SCGB1A1 coated plates (2 ug/ml and 100 ul/well), approximately >30% will adhere after one hour at 37 °C.
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Binds phosphatidylcholine, phosphatidylinositol, polychlorinated biphenyls (PCB) and weakly progesterone, potent inhibitor of phospholipase A2.
Subcellular Location Secreted.
Protein Families Secretoglobin family
Database References
Tissue Specificity Clara cells (nonciliated cells of the surface epithelium of the pulmonary airways).

Gene Functions References

  1. There was no evidence that serum CC16 levels played a role in recurrent wheezing and a positive asthma predictive index in pre-school children PMID: 29685782
  2. Data suggest that the increase in plasma club cell protein (CC16) CC16 following inhaled allergen as a biomarker of epithelial dysfunction. PMID: 28862880
  3. We propose that increased CC-16 levels is a marker of lung inflammatory response that associated with ventilatory insufficiency are related to impending respiratory failure, not fully predicted by conventional respiratory tests PMID: 28967121
  4. Studied serum CC16 levels in The serum CC16 levels in Acute respiratory distress syndrome (ARDS) and non-ARDS patients; found CC16 to be were significantly higher in ARDS patients than that in non-ARDS patients. PMID: 28548310
  5. Studied serum CC16 levels in relation to atopy and previously manifested low respiratory tract diseases. Found low serum CC16 is associated with previously expressed pneumonia and chronic wheezing in atopic children. PMID: 28146340
  6. Our data suggest that rCC16 suppresses LPS-mediated inflammatory mediator TNF-alpha, IL-6, and IL-8 production by inactivating NF-kappaB and p38 MAPK but not AP-1 in RAW264.7 cells. PMID: 28338974
  7. There were associations between urinary CC16 and arsenic concentration in soil, water, house dust, and dust loading. In multiple analyses, only the concentration of arsenic in soil was associated with urinary CC16 levels after accounting for other factors. PMID: 27223295
  8. findings demonstrate that CC16 is upregulated in IPF patients suggesting that may participate in its pathogenesis. PMID: 27977812
  9. The G38A CCSP gene polymorphism may alter either the production of the protein and/or its activity in chronic obstructive pulmonary disease. PMID: 27496897
  10. CC16 levels differed among idiopathic pulmonary fibrosis, pulmonary sarcoidosis and chronic pulmonary obstructive disease. PMID: 27758987
  11. Lung-specific (CC-16) and novel (RelB) biomarkers are associated with systemic cardiovascular changes over time. CC-16 can predict subsequent exacerbations in subjects with severe COPD and may be an important biomarker of pulmonary and systemic stress in COPD. PMID: 26914709
  12. The serum concentration of CC16 was significantly higher in patients with lung fibrosis. PMID: 25244495
  13. lower levels of urine CC16 and lung function in patients with asthma than in those patients without asthma. CC16 in urine may be a useful tool or biomarker for investigating lung epithelium integrity among children with asthma or lung injury. PMID: 26108072
  14. Smokers and COPD patients had reduced airway CC16 immunostaining that decreased with increasing COPD severity. PMID: 25700379
  15. the uteroglobin G38A gene polymorphism was not associated with IgAN risk PMID: 25068828
  16. Sputum and bronchoalveolar lavage fluid CC16 were significantly higher in patients with severe asthma compared to mild-moderate asthma and healthy controls. PMID: 25728058
  17. In chromium-exposed workers, blood levels of CC16, and CC16/SP-D were lower than in controls. Positive relationships were shown between CC16 or CC16/SP-D and indicators of lung function. PMID: 25851191
  18. KL-6 levels were higher and CC16 levels were lower in infants with poor neurodevelopmental outcome compared with those infants who had favourable neurodevelopmental outcome. PMID: 25631862
  19. CC16 may play an important protective role in cigarette smoke-related diseases. PMID: 25635997
  20. A meta-analysis indicated that the CC16 gene A38G polymorphism is not associated with the risk of asthma. PMID: 25743006
  21. Increased plasma clara cell secretory protein levels are associated with primary graft dysfunction. PMID: 24400993
  22. Uteroglobin is a possible ligand of the lipoxin receptor and it may have a role in inhibiting serum amyloid A-driven inflammation PMID: 24782597
  23. Athletes with decreased serum CC16 from regular high-load exercise are more susceptible to respiratory infections. PMID: 24735334
  24. A single therapeutic dose of terbutaline offers significant protection against hyperpnoea-induced bronchoconstriction and reduces urinary CC16 protein levels. PMID: 24030662
  25. Lung permeability biomakers [surfactant protein D (SP-D) and Clara cell secretory protein (CC16) in plasma] and forced expiratory volumes and flow were measured in swimmers in indoor swimming pool waters treated with different disinfection methods. PMID: 23874631
  26. Serum CC-16 is associated with disease progression in chronic obstructive pulmonary disease (COPD). However, the absence of CC-16 does not appear to modify the risk of cigarette-related COPD in mice. PMID: 24245748
  27. Acute exposure to smoke induces injury at the alveolar level, which results in a transient increase of CC16 in serum of exposed subjects. PMID: 23258467
  28. These results suggest that the CC16 A38G polymorphism may play a role in asymptomatic airway hyper-responsiveness and contribute to the development of late-onset asthma. PMID: 24125144
  29. The SCGB1A1 +38A/G polymorphism is a risk factor for asthma. [Meta-analysis] PMID: 23820082
  30. urinary CC16 may be a useful biomarker of increased lung epithelial permeability among female non-smokers; further work will be required to evaluate its applicability to males PMID: 22805990
  31. Clara cell secretory protein expression changes is a relevant marker in the development of bronchiolitis obliterans patients with lung transplantation. PMID: 22883104
  32. Overview of CC16 in pathophysiology of and as a biomarker in chronic obstructive pulmonary disease. PMID: 23030587
  33. A Genome wide association study for COPD biomarkers on subjects with COPD found 2 discrete loci affecting CC16, one near the CC16 coding gene (SCGB1A1) on chromosome 11 and one approximately 25Mb away from SCGB1A1, identified in expressed sputum. PMID: 23144326
  34. Donor CCSP A38G polymorphism is associated with decreased CCSP levels early after lung transplantation and poor long-term outcomes. PMID: 22902791
  35. Exercise caused an increase in urinary excretion of CC16 in all subjects (P < 0.001), but this rise in CC16 was blunted following inhalation of warm humid air. PMID: 21799131
  36. demonstration that cc-10 is differentially expressed in infants with iRDS may point the way towards one possible mechanism that potentially involves modifications of the protein structure with its anti-inflammatory and surfactant protective function PMID: 22613976
  37. CC10 G+38A variant may contribute to the severity of asthma and lower level of steroid responsiveness. PMID: 22788242
  38. These results indicate that CC10 gene transfer may inhibit airway inflammation through suppressing the activation of NF-kappaB. PMID: 22558282
  39. Serum Clara cell secretory protein levels were characterized by an early postnatal surge. This apparent gestation-influenced surge may represent an initiation of a protective cascade against postnatal lung injury during extrauterine adaptation. PMID: 21952535
  40. Single-nucleotide polymorphism in the CC10 gene (A38G) does not seem to be involved in the severity of respiratory syncytial virus infection or wheezing. PMID: 21767304
  41. Urinary levels of CC16 are increased after eucapnic voluntary hyperpnea. PMID: 21131866
  42. Elevated circulating CC16 levels identified severe thoracic injury combined with a strong correlation with the extent/volume of affected lung tissue. PMID: 21045740
  43. CC16 38A/38A genotype plays a role in the development of early asthma in children with AR. PMID: 21255142
  44. Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction. PMID: 21299834
  45. In the context of allergic airway responses, CC10 can inhibit OPN expression and suppress the Th2-promoting function of OPN, resulting in CC10's inhibitory biological effects. PMID: 20553297
  46. Data suggest that a supernatant of non-small-cell lung cancer causes an imbalance in the immune response of PBMCs and DCs, which is reversed by CC-10. PMID: 20664959
  47. Letter: serum CCSP cannot be used as a biomarker predictive for bronchiolitis obliterans after lung transplantation. PMID: 20683434
  48. Reduced anti-inflammatory CC10 concentrations in airways of extremely premature infants with a fetal inflammatory response, not umbilical cord serum CC10, might make their lungs susceptible for further postnatal injuries. PMID: 19887851
  49. Association of CC16 with daily outdoor particulate matter from combustion sources increases epithelial barrier permeability in lungs. PMID: 19852548
  50. The effect of G38A may be apparent under stimulation as sex steroids or infections, and homozygotes of the G38A mutation cannot produce sufficient UG in response to stimulation and may be predisposed to IgA nephropathy, especially in childhood. PMID: 11774099


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed